PLATAR PHASE II TRIAL, New York City and Houston, Texas
New Experimental Mesothelioma Trial Sponsored by the FDA Orphan Drug Act conducted at the New York University Kaplan Comprehensive Comprehensive Cancer Center
L-NDDP:
- New creamy platinum compound delivered in a liposome carrier.
- Administered intrapleurally causes minimal local and systemic toxicity.
- Resulted in biopsy-documented complete response in about 61% of cases.
- Patients are eligible if they have had prior surgery, radiation, and/or chemotherapy.
- All patients must have a free-flowing pleural effusion.
For more information, please call (212) 263-8043 or (212) 263-6485
Or
Email: lyj01@kccc.med.nyu.edu
At the M.D. Anderson Medical Center in Houston, Texas, a phase II study of mesothelioma with pleural decortication, LNDDP (Platar), and radiotherapy is currently open for pleural mesothelioma, and the phase I of intraperitoneal LNDDP is still open for accrual. Patients with peritoneal mesothelioma are welcome. For pleural mesothelioma, call (713)792-6363 and have patients speak with Dr. Shin, and for peritoneal mesothelioma call Dr. Claire Verschraegen at (713)792-7959.
** POSTED MAY 7, 1999 **
Note: Intraperitoneal PLATAR suspended at MD Anderson,
9/7/99
We just received news that that the Platar trial at MD Anderson in
Houston, Texas has been suspended due to toxicity. The trial in New
York for pleural mesothelioma is continuuing. I have contacted Dr.
Verschraegen at MDAnderson to confirm this report. More to follow.
RGW
** POSTED SEPTEMBER 9, 1999 **